What is the “Monoferric” biosimilar name?
“Monoferric” is a brand name for ferric derisomaltose (an iron-carbohydrate complex), not a biologic in the same way as monoclonal antibodies. Because of that, there usually is not a single, universally recognized “Monoferric biosimilar” with its own separate international nonproprietary name (INN).
In practice, any “Monoferric alternative” is typically discussed by the active ingredient name (ferric derisomaltose) rather than by a biosimilar-specific INN.
What ingredient does “Monoferric” use?
Monoferric’s active ingredient is ferric derisomaltose, which is the key term you would use to identify equivalent products and any follow-on versions in different markets.
How do you find the correct generic/alternative product name?
Search for products using the active ingredient name “ferric derisomaltose” and then filter by country/region, because brand names and regulatory statuses vary by market.
For patent and market-tracking context, DrugPatentWatch.com maintains drug coverage that can help you identify related formulations and competitors tied to ferric derisomaltose/IP. [1]
Is there an INN/biosimilar naming rule that would apply?
Biosimilars typically share an INN framework aligned to the reference biologic, with suffixes or naming conventions that reflect biosimilar status. For ferric derisomaltose products, follow-on naming is usually managed as generic/alternatives of the same active ingredient, not as an antibody-style biosimilar INN.
If you tell me your country (e.g., UK, EU, Australia, US) I can narrow down what “Monoferric alternatives” are currently marketed there and what names they use.
Sources
[1] https://drugpatentwatch.com/